{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:45:38Z","timestamp":1772495138157,"version":"3.50.1"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2016-0031_s_013_w2aab2b8c40b1b7b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      DLBS3233, a combined bioactive fraction of\n                      <jats:italic>Cinnamomum burmanii<\/jats:italic>\n                      and\n                      <jats:italic>Lagerstroemia speciosa<\/jats:italic>\n                      , has preclinically demonstrated its beneficial effects on glucose and lipid metabolism through the upregulation of insulin-signal transduction. This study evaluated the clinical efficacy of an add-on therapy with DLBS3233 in type-2 diabetes mellitus subjects inadequately controlled by metformin and other oral antidiabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2016-0031_s_014_w2aab2b8c40b1b7b1aab1c14b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was an open and prospective clinical study for 12 weeks of therapy, involving type-2 diabetes mellitus patients who had been treated with two oral antidiabetic agents for at least 3 months prior to screening, yet, with HbA\n                      <jats:sub>1c<\/jats:sub>\n                      level was still beyond 7.0\u2006%. DLBS3233 was given orally at the dose of 100 mg once daily in addition to their baseline oral antidiabetes medication. The primary end point was the reduction of HbA\n                      <jats:sub>1c<\/jats:sub>\n                      level; and the secondary end points were changes of fasting and 1-h postprandial glucose, homeostatic model assessment-insulin resistance, adiponectin, and lipid profile, from their respective baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2016-0031_s_015_w2aab2b8c40b1b7b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 12 weeks of treatment, the HbA\n                      <jats:sub>1c<\/jats:sub>\n                      level was reduced by 0.65\u00b11.58\u2006% (p=0.001) from baseline (9.67\u00b12.11\u2006%); while the 1-h-PG level was reduced by \u20131.45\u00b13.89\u2006mmol\/L (p=0.021) from baseline (15.29\u00b14.49\u2006mmol\/L). Insulin sensitivity, lipid profile and adiponectin level were improved to a considerable extent. DLBS3233 did not adversely affect body weight, liver, and renal function. Most adverse events observed were tolerably mild and they all had been resolved by the end of the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2016-0031_s_016_w2aab2b8c40b1b7b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The add-on oral antidiabetes therapy with DLBS3233 at the dose of 100 mg once daily helped type-2 diabetes mellitus patients to improve their glycemic control, enhance insulin sensitivity, lipid profile, and adiponectin level. In addition, DLBS3233 treatment concomitantly with other oral antidiabetic agents was proven safe and tolerable in type-2 diabetes subjects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2016-0031","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T05:01:32Z","timestamp":1479877292000},"page":"413-420","source":"Crossref","is-referenced-by-count":9,"title":["DLBS3233, a combined bioactive fraction of\n                    <i>Cinnamomum burmanii<\/i>\n                    and\n                    <i>Lagerstroemia speciosa<\/i>\n                    , in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents"],"prefix":"10.1515","volume":"13","author":[{"given":"Askandar","family":"Tjokroprawiro","sequence":"first","affiliation":[{"name":"Surabaya Diabetes and Nutrition Centre, Dr. Soetomo Hospital, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri","family":"Murtiwi","sequence":"additional","affiliation":[{"name":"Surabaya Diabetes and Nutrition Centre, Dr. Soetomo Hospital, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond R.","family":"Tjandrawinata","sequence":"additional","affiliation":[{"name":"Dexa Laboratories of Biomolecular Sciences, Dexa Medica Group, Industri Selatan V, Block PP no.\u20067, Kawasan Industri Jababeka II, Cikarang 17550, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,7,23]]},"reference":[{"key":"2025121209202571360_j_jcim-2016-0031_ref_001_w2aab2b8c40b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl. 1):S81\u201390.","DOI":"10.2337\/dc14-S081"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_002_w2aab2b8c40b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"2. American Diabetes Association. Standards of medical care in diabetes \u2013 2015. Diabetes Care 2015;38(Suppl. 1):S1\u201393.","DOI":"10.2337\/dc15-1773"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_003_w2aab2b8c40b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"3. Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR. Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPAR\u03b3 and GLUT4 expression. Int J Gen Med 2011;4: 345\u201357.","DOI":"10.2147\/IJGM.S16517"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_004_w2aab2b8c40b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"4. Nailufar F, Tandrasasmita OM, Tjandrawinata RR. DLBS3233 increases glucose uptake by mediating upregulation of PPAR\u03b3 and PPAR\u03b4 expression. Biomed Prev Nutr 2011;1:71\u20138.","DOI":"10.1016\/j.bionut.2010.12.002"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_005_w2aab2b8c40b1b7b1ab2b1b5Aa","unstructured":"5. Sukandar EY, Sigit JI, Adnyana IK. Acute toxicity of DLBS 3233. Study report. Bandung: Bandung Institute of Technology, 2008."},{"key":"2025121209202571360_j_jcim-2016-0031_ref_006_w2aab2b8c40b1b7b1ab2b1b6Aa","unstructured":"6. Sukandar EY, Sigit JI, Adnyana IK. Subchronic toxicity of DLBS 3233. Study report. Bandung: Bandung Institute of Technology, 2008."},{"key":"2025121209202571360_j_jcim-2016-0031_ref_007_w2aab2b8c40b1b7b1ab2b1b7Aa","unstructured":"7. Sukandar EY, Sigit JI, Adnyana IK. Teratogenic effect of DLBS 3233. Study report. Bandung: Bandung Institute of Technology, 2008."},{"key":"2025121209202571360_j_jcim-2016-0031_ref_008_w2aab2b8c40b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"8. Tjandrawinata RR, Suastika K, Nofiarny D. DLBS3233 extract, a novel insulin sensitizer with negligible risk of hypoglycemia: a phase-I study. Int J Diabetes Metab 2012;21:13\u201320.","DOI":"10.1159\/000497721"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_009_w2aab2b8c40b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"9. Manaf A, Tjandrawinata RR, Malinda D. Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum Burmanii and Lagerstroemia speciosa. Drug Des Dev Ther 2016;10:1279\u201389.","DOI":"10.2147\/DDDT.S97568"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_010_w2aab2b8c40b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"10. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368\u201373.","DOI":"10.1055\/s-0028-1104604"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_011_w2aab2b8c40b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"11. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083\u201391.","DOI":"10.2337\/diacare.28.5.1083"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_012_w2aab2b8c40b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"12. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733\u201345.","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_013_w2aab2b8c40b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"13. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410\u20138.","DOI":"10.1001\/jama.2010.405"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_014_w2aab2b8c40b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"14. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization\/lipid lowering in rats. BMC Pharmacol 2004;4:23.","DOI":"10.1186\/1471-2210-4-23"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_015_w2aab2b8c40b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"15. Spranger J, Kroke A, M\u00f6hlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226\u20138.","DOI":"10.1016\/S0140-6736(03)12255-6"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_016_w2aab2b8c40b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"16. Yamamoto S, Matsushita Y, Nakagawa T, Hayashi T, Noda M, Mizoue T. Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. Nutr Diabetes 2014;4:e130.","DOI":"10.1038\/nutd.2014.27"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_017_w2aab2b8c40b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"17. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991;229:181\u20137.","DOI":"10.1111\/j.1365-2796.1991.tb00328.x"},{"key":"2025121209202571360_j_jcim-2016-0031_ref_018_w2aab2b8c40b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"18. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172\u20138.","DOI":"10.2337\/diacare.26.1.172"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jcim.2016.13.issue-4\/jcim-2016-0031\/jcim-2016-0031.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2016-0031\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2016-0031\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:13:08Z","timestamp":1765541588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2016-0031\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,23]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,7,23]]},"published-print":{"date-parts":[[2016,12,1]]}},"alternative-id":["10.1515\/jcim-2016-0031"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2016-0031","relation":{},"ISSN":["2194-6329","1553-3840"],"issn-type":[{"value":"2194-6329","type":"print"},{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,23]]}}}